Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · X4 Pharmaceuticals, Inc (XFOR)

X4 Pharmaceuticals signs up to $150 million term loan, repays Hercules debt

Neutral Impact 4 of 5 financing Written later

On October 7, 2026, X4 Pharmaceuticals and its subsidiary X4 Therapeutics entered a Loan and Security Agreement with K2 HealthVentures providing term loans of up to $150.0 million. An $80.0 million first tranche funded at closing and was used to repay in full the Hercules loan, with a total payoff of approximately $78.7 million. For shareholders, the deal refinances existing debt and adds up to $70.0 million of possible further borrowing, but it carries variable-rate interest, secured liens, financial covenants, and a conversion feature that could issue common stock.

Key points

  • First tranche of $80.0 million funded October 7, 2026; up to $70.0 million more available at the company's request, subject to lender review and discretionary approval.
  • Hercules payoff of approximately $78.7 million, including $75.0 million of principal, ended the prior Hercules Loan Agreement and released its liens.
  • Cash interest is the greater of 8.55% or the WSJ prime rate plus 1.55%, plus 1.0% paid-in-kind interest; interest-only through October 1, 2029; maturity October 1, 2030.
  • Lenders may convert up to $15.0 million of principal into common stock at $3.2341 per share; minimum cash covenant applies from October 1, 2027 when market capitalization is below $800.0 million.

The filing

CompanyX4 Pharmaceuticals, Inc (XFOR)
Form8-K, current report
Filed with the SECOct 8, 2026, 5:23 PM ET
Accession number0001501697-26-000081

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.